Ad is loading...
ALLO
Price
$2.27
Change
-$0.19 (-7.72%)
Updated
Nov 15 closing price
101 days until earnings call
VRDN
Price
$20.14
Change
-$1.50 (-6.93%)
Updated
Nov 15 closing price
101 days until earnings call
Ad is loading...

ALLO vs VRDN

Header iconALLO vs VRDN Comparison
Open Charts ALLO vs VRDNBanner chart's image
Allogene Therapeutics
Price$2.27
Change-$0.19 (-7.72%)
Volume$3.09M
CapitalizationN/A
Viridian Therapeutics
Price$20.14
Change-$1.50 (-6.93%)
Volume$1.83M
CapitalizationN/A
ALLO vs VRDN Comparison Chart
Loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ALLO vs. VRDN commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALLO is a Sell and VRDN is a StrongSell.

COMPARISON
Comparison
Nov 18, 2024
Stock price -- (ALLO: $2.27 vs. VRDN: $20.14)
Brand notoriety: ALLO and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALLO: 142% vs. VRDN: 136%
Market capitalization -- ALLO: $475.96M vs. VRDN: $1.6B
ALLO [@Biotechnology] is valued at $475.96M. VRDN’s [@Biotechnology] market capitalization is $1.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $472.8B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALLO’s FA Score shows that 0 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • ALLO’s FA Score: 0 green, 5 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, VRDN is a better buy in the long-term than ALLO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALLO’s TA Score shows that 5 TA indicator(s) are bullish while VRDN’s TA Score has 3 bullish TA indicator(s).

  • ALLO’s TA Score: 5 bullish, 4 bearish.
  • VRDN’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ALLO is a better buy in the short-term than VRDN.

Price Growth

ALLO (@Biotechnology) experienced а -26.30% price change this week, while VRDN (@Biotechnology) price change was -20.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.58%. For the same industry, the average monthly price growth was -5.90%, and the average quarterly price growth was -0.16%.

Reported Earning Dates

ALLO is expected to report earnings on Feb 26, 2025.

VRDN is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-8.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($1.6B) has a higher market cap than ALLO($476M). VRDN YTD gains are higher at: -7.530 vs. ALLO (-29.283). VRDN has higher annual earnings (EBITDA): -224.78M vs. ALLO (-256.56M). VRDN has more cash in the bank: 571M vs. ALLO (445M). VRDN has less debt than ALLO: VRDN (21M) vs ALLO (87M). VRDN has higher revenues than ALLO: VRDN (288K) vs ALLO (65K).
ALLOVRDNALLO / VRDN
Capitalization476M1.6B30%
EBITDA-256.56M-224.78M114%
Gain YTD-29.283-7.530389%
P/E RatioN/AN/A-
Revenue65K288K23%
Total Cash445M571M78%
Total Debt87M21M414%
FUNDAMENTALS RATINGS
ALLO vs VRDN: Fundamental Ratings
ALLO
VRDN
OUTLOOK RATING
1..100
659
VALUATION
overvalued / fair valued / undervalued
1..100
97
Overvalued
95
Overvalued
PROFIT vs RISK RATING
1..100
10066
SMR RATING
1..100
9597
PRICE GROWTH RATING
1..100
8043
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRDN's Valuation (95) in the Biotechnology industry is in the same range as ALLO (97). This means that VRDN’s stock grew similarly to ALLO’s over the last 12 months.

VRDN's Profit vs Risk Rating (66) in the Biotechnology industry is somewhat better than the same rating for ALLO (100). This means that VRDN’s stock grew somewhat faster than ALLO’s over the last 12 months.

ALLO's SMR Rating (95) in the Biotechnology industry is in the same range as VRDN (97). This means that ALLO’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Price Growth Rating (43) in the Biotechnology industry is somewhat better than the same rating for ALLO (80). This means that VRDN’s stock grew somewhat faster than ALLO’s over the last 12 months.

VRDN's P/E Growth Rating (100) in the Biotechnology industry is in the same range as ALLO (100). This means that VRDN’s stock grew similarly to ALLO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALLOVRDN
RSI
ODDS (%)
N/A
Bearish Trend 3 days ago
82%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 14 days ago
80%
Bullish Trend 7 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
84%
Bearish Trend 3 days ago
84%
Aroon
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
85%
View a ticker or compare two or three
Ad is loading...
ALLO
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VRDN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RWIIX14.34N/A
N/A
Redwood AlphaFactor Tactical Intl I
TRLCX23.69-0.06
-0.25%
Nuveen Large Cap Value Retire
HDVIX12.35-0.07
-0.56%
Hartford International Equity I
SRIAX14.15-0.08
-0.56%
Gabelli SRI A
CLSPX31.02-0.54
-1.71%
Columbia Select Mid Cap Gro Fd I

ALLO and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALLO has been loosely correlated with FATE. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ALLO jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALLO
1D Price
Change %
ALLO100%
-7.72%
FATE - ALLO
58%
Loosely correlated
-2.88%
NTLA - ALLO
56%
Loosely correlated
-7.61%
BEAM - ALLO
55%
Loosely correlated
-8.59%
CRSP - ALLO
54%
Loosely correlated
+0.85%
CRBU - ALLO
54%
Loosely correlated
-4.78%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with FATE. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
-6.93%
FATE - VRDN
50%
Loosely correlated
-2.88%
ALLO - VRDN
50%
Loosely correlated
-7.72%
CRBU - VRDN
48%
Loosely correlated
-4.78%
ABCL - VRDN
46%
Loosely correlated
-3.99%
ALEC - VRDN
46%
Loosely correlated
-17.21%
More